The American Life Sciences Innovation Council (ALSIC) is a social welfare organization created in 2010 to support policies that foster an environment in which medical innovation can thrive. Our mission is to educate the public and policymakers about the effects of government regulation on key factors that drive life science innovation.

Key Factors Driving Life Science Innovation

  • Strong intellectual property protection
  • Adequate reimbursement driven by market forces
  • Unfettered collaboration with basic science partners
  • A transparent and predictable regulatory environment
  • Access to capital

What We Do

ALSIC engages thought leaders, trade and professional associations, policymakers, and the general public through long-term advocacy campaigns to bring attention to policies that will promote innovation in the life sciences. Additionally, ALSIC communicates its message on the issues surrounding life science innovation to the public through all forms of mass communication—including, but not limited to, print advertising, cable television and radio messaging, as well as e-mail and direct-mail communications.

ALSIC shares its research and policy positions with policymakers and encourage its supporters and the general public to communicate their views on these issues at all levels of government. ALSIC seeks the commitment of these policymakers to implement statutes, rules, and regulations consistent with principles supporting life science innovation.

Board of Directors

William Harrison
Mr. Harrison is a regulatory and quality assurance expert in drug development, and is the President and Chief Executive Officer of VIDA Sciences. He formerly held positions of increasing responsibility, including President and Chief Operating Officer, at MPI Research, a large contract research organization that provides extensive preclinical management services. Mr. Harrison has also served as the President of the Society of Quality Assurance.

Joseph Dunn, Ph.D.
Dr. Dunn is a thought-leader, public servant and experienced researcher in the life sciences. His past positions include Senior Scientific Advisor and Deputy Under-Secretary for the United States Department of Agriculture and Senior Research Investigator for The Colgate Palmolive and Eastman Kodak Companies. He presently serves as the Chief Executive Officer and Director of Research at OmniPharm Research International as well as Associate Dean for Research and Professor of Pharmaceutical Sciences at D’Youville College School of Pharmacy. Dr. Dunn is a patented inventor and is widely-published in areas spanning from antiviral chemotherapy to bioenergy.

H. Dean Hart
Mr. Hart is an accomplished executive in the life sciences arena with decades of commercial experience including directing national sales and marketing for several leading pharmaceutical manufacturers. He presently serves as the Chief Commercial Officer of NanoInk, Inc., an emerging growth technology company specializing in nanometer-scale applications for the life sciences and pharmaceutical industry. In this role, Mr. Hart directly oversees the company’s pharmaceutical supply chain security and brand protection division and provides strategic consulting for NanoInk’s other commercial entities.

Steve Knuth
Mr. Knuth is a 20-year veteran in the fields of alliance development and grassroots advocacy. He serves as the Chief Executive Officer at Public Affairs Company, a Minneapolis-based government relations firm with more than a decade of experience in the health care arena. Mr. Knuth’s work includes extensive experience in assisting the life sciences industry in nationwide, coordinated advocacy efforts on health policy initiatives.

David Mohler
Mr. Mohler is a leading public policy attorney and consultant to the life sciences industry. He has more than 15 years of experience advising biotech, pharmaceutical, medical device and other life science clients and trade associations on the federal level. Mr. Mohler’s policy and advocacy experience spans a number of areas including federal regulations and legislation affecting patients and manufacturers.